Anacor Pharma Reports Presentations of Crisaborole Topical Ointment, 2% Phase 3 Pivotal Data at Two Upcoming Conferences

Loading...
Loading...
Anacor Pharmaceuticals, Inc.
ANAC
announced today that data from the Phase 3 pivotal studies of investigational drug Crisaborole Topical Ointment, 2% will be presented at two upcoming medical meetings. The Fall Clinical Dermatology Conference, October 1-4, 2015 in Las Vegas, Nevada The following abstracts have recently been accepted for poster presentation: "Results from Two Phase 3 Studies in Children and Adults with Mild to Moderate Atopic Dermatitis Treated with Crisaborole Topical Ointment, 2%, a Novel Nonsteroidal, Topical Anti-Inflammatory, Phosphodiesterase 4 Inhibitor" "Evaluation of Pruritus and Signs of Atopic Dermatitis With Crisaborole Topical Ointment, 2%, a Novel Nonsteroidal, Topical Anti-Inflammatory, Phosphodiesterase 4 Inhibitor in Two Phase 3 Studies in Children and Adults With Mild to Moderate Atopic Dermatitis" The 24th European Academy of Dermatology and Venereology Congress, October 7-11, 2015 in Copenhagen, Denmark LATCOP-0093, "Treatment of children and adults with mild to moderate atopic dermatitis with Crisaborole Topical Ointment, 2%, a novel, nonsteroidal, topical anti-inflammatory, phosphodiesterase 4 inhibitor: results from two phase 3 studies" will be presented during the late breaking news session on Saturday, October 10, between 8:00 a.m. and 11:15 a.m. CEST by Mark Lebwohl, M.D., Sol and Clara Kest Professor and Chair of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai.
Loading...
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...